The differential effects of statins on the metastatic behaviour of prostate cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown. METHODS: Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non-malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins. RESULTS: Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1 μM) and rosuvastatin (5 μM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93-77.04%; P<0.05) and significantly reducing both number (76.2±8.29 vs 122.9±2.48; P=0.0055) and size (0.2±0.0058 mm(2) vs 0.27±0.012 mm(2); P=0.0019) of colonies formed within BMS. Statin-treated colonies displayed a more compact morphology containing cells of a more epithelial phenotype, indicative of a reduction in the migrational ability of PC-3 cells. Normal PC-3 phenotype and invasive ability was recovered by the addition of geranylgeranyl pyrophosphate (GGPP). CONCLUSION: Lipophilic statins reduce the migration and colony formation of PC-3 cells in human BMS by inhibiting GGPP production, reducing the formation and the spread of metastatic prostate colonies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statins: mechanism of action and effects
Stancu, C., & Sima, A. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00172.x · Cited by 911 · cited 3×
“The basis for these observations is poorly understood but the effects probably relate to the pleiotropic actions of 3-hydroxy-3methylglutaryl-CoA (HMG-CoA) inhibitors on cellular behaviour, cell-cell interaction and cellular motility in relation to lipid metabolism (Stancu and Sima, 2001).”
BackgroundZhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200519935 · Cited by 567 · cited 1×
“Treatment of CaP overnight or glioma cells for 48 h with simvastatin induced a 70% reduction in lipid raft cholesterol, an effect reversed by addition of exogenous cholesterol (Zhuang et al, 2005; Wu et al, 2009).”
Background
Cited by
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 292
Rye, M. B., Bertilsson, H., Andersen, M. K., Rise, K., Bathen, T. F., Drabløs, F., & Tessem, M.-B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4373-y · Cited by 21
Rimpelová, S., Kolář, M., Strnad, H., Ruml, T., Vítek, L., & Gbelcová, H. (2021) · Molecules · doi:10.3390/molecules26123528 · Cited by 8
Metadata
- Authors
- Brown, M., Hart, C., Tawadros, T., Ramani, V, Sangar, V, Lau, M., & Clarke, N.
- Venue
- British Journal of Cancer
- Published
- 2012-04-24
- Volume
- 106
- Issue
- 10
- Pages
- 1689-1696
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1977834924
- Cited by
- 94
- References
- 2
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.